Right ventricular (RV) failure is by far the most common cause of death in patients with pulmonary arterial hypertension (PAH). At present, little is known of the mechanisms contributing to RV failure in the setting of PAH. It is increasingly appreciated that it is not due simply to distal pulmonary microvascular disease and high pulmonary vascular resistance but rather to complex interactions between the pulmonary circulation and the RV. Inflammation is known to contribute significantly to changes in vascular remodeling in both large and small vessels as well as to RV dysfunction, especially in scleroderma associated PAH (SSc-PAH). Circulating mononuclear-fibrogenic cells have been implicated in inflammation, vascular remodeling, and RV dysfunction by our group and others. We have shown that fibroblasts in PAH patients and in animal models acquire an activated and epigenetically altered phenotype that is capable of generating a microenvironment, which promotes recruitment and activation of circulating mononuclear fibrogenic cells and that these cells contribute directly to tissue fibrosis and cardiac dysfunction. Our proposal will directly examine the mechanisms involved in fibroblast directed recruitment and activation of mononuclear fibrogenic cells and ultimately the role of these cells in driving abnormalities of large and small vessels, RV function and ultimately RV failure. Studies will be conducted in patients and also in unique large animal models of disease that have great fidelity to the human condition. Further, because we have shown that histone modifications are involved in the epigenetic change in fibroblast phenotype and that histone deacetylase inhibitors (HDACi) can turn off inflammatory signaling by activated fibroblasts, we will pursue studies to determine whether isoform selective HDAC inhibition can reverse pre-existing pulmonary hypertension and cardiac dysfunction by reprogramming epigenetically imprinted pro-inflammatory fibroblasts in the vasculature and right ventricle. Our proposal involves a multi- disciplinary approach with Principal Investigators with expertise in clinical pulmonary hypertension, in molecular cardiology, and in cell and molecular biology of fibroblasts and circulating mononuclear cells. Collectively, work by this interdisciplinary group will provide insight into abnormalities of RV-pulmonary arterial interactions in the setting of severe pulmonary hypertension and will lay the groundwork for potential new therapies.

Public Health Relevance

The most common cause of death in patients with pulmonary hypertension is failure of the right side of the heart. Much remains to be learned about why the right heart fails in pulmonary hypertension especially because current therapies are not particularly effective in improving right heart function. We are proposing studies in humans and animals to better understand why the right heart fails and to evaluate the potential for a novel drug therapy beginning with testing in animals.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL114887-01
Application #
8354554
Study Section
Special Emphasis Panel (ZHL1-CSR-H (M1))
Program Officer
Moore, Timothy M
Project Start
2012-08-15
Project End
2017-06-30
Budget Start
2012-08-15
Budget End
2013-06-30
Support Year
1
Fiscal Year
2012
Total Cost
$681,080
Indirect Cost
$238,820
Name
University of Colorado Denver
Department
Pediatrics
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Schäfer, Michal; Myers, Cynthia; Brown, R Dale et al. (2016) Pulmonary Arterial Stiffness: Toward a New Paradigm in Pulmonary Arterial Hypertension Pathophysiology and Assessment. Curr Hypertens Rep 18:4
Bartels, Karsten; Brown, R Dale; Fox, Daniel L et al. (2016) Right Ventricular Longitudinal Strain Is Depressed in a Bovine Model of Pulmonary Hypertension. Anesth Analg 122:1280-6
Stenmark, Kurt R; Frid, Maria; Perros, Frédéric (2016) Endothelial-to-Mesenchymal Transition: An Evolving Paradigm and a Promising Therapeutic Target in PAH. Circulation 133:1734-7
Li, Min; Riddle, Suzette; Zhang, Hui et al. (2016) Metabolic Reprogramming Regulates the Proliferative and Inflammatory Phenotype of Adventitial Fibroblasts in Pulmonary Hypertension Through the Transcriptional Corepressor C-Terminal Binding Protein-1. Circulation 134:1105-1121
Irwin, David C; Baek, Jin Hyen; Hassell, Kathryn et al. (2015) Hemoglobin-induced lung vascular oxidation, inflammation, and remodeling contribute to the progression of hypoxic pulmonary hypertension and is attenuated in rats with repeated-dose haptoglobin administration. Free Radic Biol Med 82:50-62
Lemon, Douglas D; Harrison, Brooke C; Horn, Todd R et al. (2015) Promiscuous actions of small molecule inhibitors of the protein kinase D-class IIa HDAC axis in striated muscle. FEBS Lett 589:1080-8
Nagel, Maria A; Choe, Alexander; Rempel, April et al. (2015) Differential regulation of matrix metalloproteinases in varicella zoster virus-infected human brain vascular adventitial fibroblasts. J Neurol Sci 358:444-6
Stenmark, Kurt R; Tuder, Rubin M; El Kasmi, Karim C (2015) Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxic pulmonary hypertension. J Appl Physiol (1985) 119:1164-72
Bruns, Danielle R; Brown, R Dale; Stenmark, Kurt R et al. (2015) Mitochondrial integrity in a neonatal bovine model of right ventricular dysfunction. Am J Physiol Lung Cell Mol Physiol 308:L158-67
Mandell, Erica; Powers, Kyle N; Harral, Julie W et al. (2015) Intrauterine endotoxin-induced impairs pulmonary vascular function and right ventricular performance in infant rats and improvement with early vitamin D therapy. Am J Physiol Lung Cell Mol Physiol 309:L1438-46

Showing the most recent 10 out of 62 publications